Halozyme Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $290,084 | $231,353 | $195,879 | $230,039 |
Gross Profit | 240,658 | 173,984 | 149,787 | 177,741 |
EBITDA | 190,033 | 137,597 | 115,748 | 127,088 |
EBIT | 169,671 | 117,235 | 95,542 | 106,395 |
Net Income | 137,011 | 93,245 | 76,823 | 85,388 |
Net Change In Cash | 290,084 | 231,353 | 195,879 | 230,039 |
Free Cash Flow | 113,859 | 53,212 | 125,881 | 99,758 |
Cash | 154,318 | 187,864 | 164,627 | 118,370 |
Basic Shares | 130,134 | 129,222 | 128,887 | 131,035 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $829,253 | $660,116 | $443,310 | $267,594 |
Gross Profit | 636,892 | 520,812 | 361,897 | 224,227 |
EBITDA | 451,947 | 315,506 | 278,899 | 147,539 |
EBIT | 367,091 | 265,865 | 275,902 | 144,255 |
Net Income | 281,594 | 202,129 | 402,710 | 129,085 |
Net Change In Cash | 829,253 | 660,116 | 443,310 | 267,594 |
Cost of Revenue | 115,476 | -28,984 | 27,524 | |
Free Cash Flow | 373,277 | 235,300 | 297,983 | 52,950 |
Cash | 118,370 | 234,195 | 118,719 | 147,703 |
Basic Shares | 134,197 | 140,608 | 146,796 | 141,463 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $1.27 |
2024-06-30 | $0.91 |
2024-03-31 | $0.79 |
2023-12-31 | $0.82 |
